{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-26-000055","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2026-08-05T20:01:16+00:00","discovered_at":"2026-08-05T20:02:00.397517+00:00","generated_at":"2026-08-05T20:02:06.645496+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xencor Q2 net loss $21.7M; Alexion settlement $105M; XmAb819 ESMO presentation","bullets":["Q2 2026 revenue $51.2M (up from $43.6M YoY); net loss $21.7M ($0.29 loss per share) vs $30.8M loss in Q2 2025.","Alexion settlement resolves Ultomiris royalty dispute: $105M total, first $52.5M due Aug 2026, second $52.5M in 2027; no further U.S. royalties.","XmAb819 (ENPP3 x CD3) Phase 1 ccRCC data accepted for oral presentation at ESMO 2026; registration-enabling study planned for 2027.","XmAb541 (CLDN6 x CD3) monotherapy shows ~14% ORR in ovarian, ~28% in germ cell tumors; FDA Fast Track for germ cell; combination with XmAb808 prioritized.","Cash $486.4M at June 30, 2026; expects year-end 2026 cash $420-440M; sufficient to fund operations through 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-26-000055","json":"https://secwatch.observer/filing/0001326732-26-000055.json","markdown":"https://secwatch.observer/filing/0001326732-26-000055.md","text":"https://secwatch.observer/filing/0001326732-26-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/0001326732-26-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673226000055/xncr-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:02:06.645496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}